Loading
A phase 1/2 trial of Darolutamide, Abiraterone acetate in prostate cancer, run by Novartis Pharmaceuticals, now recruiting.
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) is a phase 1/2 interventional study registered as NCT07190300 by Novartis Pharmaceuticals, with 181 participants planned, started 2026-01-13 and due to reach its primary completion in 2032-08-02. Interventions recorded: Tulmimetostat, Darolutamide, Abiraterone. Conditions listed: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic hormone-sensitive prostate cancer, Abiraterone acetate, Novartis, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Novartis, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/